Please login to the form below

Not currently logged in
Email:
Password:

Sosei

This page shows the latest Sosei news and features for those working in and with pharma, biotech and healthcare.

GSK signs collaboration deal with Ligand targeting neurological disorders

GSK signs collaboration deal with Ligand targeting neurological disorders

products. Another deal – signed with Sosei Heptares this week – will see GSK collaborate on the discovery and development of a small molecule target for inflammatory bowel disease and other gastrointestinal immune

Latest news

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    Dr Fiona Marshall has joined MSD from Heptares Therapeutics, the UK biotech company she co-founded more than a decade ago, which was acquired by Sosei in 2015.

  • Deal Watch March 2017 Deal Watch March 2017

    20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition–asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐oncology small molecule and other

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

  • Sosei appoints CFO Sosei appoints CFO

    Andrew Oakley joins the Tokyo-based pharma firm. Andrew Oakley has joined Tokyo-based pharmaceutical firm Sosei as chief financial officer, succeeding Hidetoshi Torami. ... Peter Bains, chief executive officer of Sosei, said: “Andrew brings a wealth of

  • Sosei appoints chief operating officer Sosei appoints chief operating officer

    Tokyo, Japan-based Sosei has appointed Peter Bains as its chief operating officer and representative executive officer. ... In this role, Bains will oversee all of the pharmaceutical firm's operational activities, reporting to Shinichi Tamura, Sosei's

  • Dr David Chiswell joins Kymab Dr David Chiswell joins Kymab

    He brings over 30 years of biotechnology expertise to the firm, having held senior management positions at a number of pharmaceutical companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei.

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...